Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of $480.00. The company’s shares closed ...

Reliable Microsoft sources have confirmed to Windows Latest that the company has already started the process of killing off the Mail & Calendar apps on Windows 11 (and Windows 10). While you can ...

Google Sheets already comes with calendar templates, so you can choose anyone to form the basis of your content calendar. Google Sheets is accessible via a web browser or mobile app. You can view ...

Using a calendar has always been an important part of our daily life, starting from being used as a way to keep track of days/dates and plan our schedules, and meetings. We also keep a calendar to ...

9 Easy Content Calendar Templates You Can Use for Free Your email has been sent A content calendar is a great way to visualize your publishing schedule. From blog posts and social media content to ...

7 Free Editorial Calendar Templates You Can Use Right Now Your email has been sent Managing content at scale is a challenge — staying organized, deciding what to post, assigning writers and ...

Get the Real Story Behind Every Major Earnings Report RBC Capital Markets says Vertex management is optimistic about the recently approved Alyftrek. They predict that most of the 6,000 patients ...

Vertex has been running a number of trials because if there’s one thing that we can take away from the failed drug development projects of the past, it’s that there are many kinds of pain.

We're kicking off the 43rd Annual Healthcare Conference this morning, and I couldn't be more delighted to introduce Vertex's CEO, Reshma Kewalramani. She's going to come on stage to give a ...

BOSTON, January 12, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the ...

--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the ...